Tumor News and Research

RSS

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Retailers join to support breast cancer research

This October, retailers nationwide are joining the fight against breast cancer by offering pink ribbon products that benefit research, treatment and education programs at City of Hope, one of the nation’s leading cancer research and treatment centers. From skin and hair care treatments to apparel to office products, consumers can feel good about their purchases and help support lifesaving cancer research.

1 Oct 2009

Social environment plays vital role in breast cancer

Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

1 Oct 2009

Todd Cancer Institute granted approval for constructing proton therapy center

The Todd Cancer Institute (TCI) at Long Beach Memorial Medical Center (LBMMC) and Miller Children’s Hospital (MCH) today announced it has been granted approval to proceed with the architecture and engineering for its proton therapy center, becoming one of only 13 centers in the country currently planning for a compact unit.

1 Oct 2009

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

For patients diagnosed with a brain tumor, St. Mary Medical Center is among the first in the region to offer Frameless Stereotactic Radiosurgery (SRS) as a breakthrough treatment to fight cancer. Frameless Stereotactic Radiosurgery is a one-time application of a large-dose radiation precisely targeting a tumor.

1 Oct 2009

NCI and NHGRI collaborate to characterize genetic and genomic changes that occur in cancers

The University of North Carolina at Chapel Hill is one of twelve centers announced today by President Obama as part of an unprecedented large-scale, collaborative effort by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to systematically characterize the genomic changes that occur in cancer.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Coupling electrosurgery with mass spectrometry for real-time identification of tumor tissues

Instead of the classic scalpel, surgeons can also operate with an electroscalpel. A significant advantage to this technique is that while a cut is being made, blood vessels are closed off and hemorrhaging eliminated. Now another advantage may be added as well: a German-Hungarian research team has developed a mass-spectrometry-based technique by which tissues can be analyzed during a surgical procedure.

30 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

AAPS Annual Meeting to discuss new research and technologies in pharmaceutical sciences

More than 8,500 individuals from the field of pharmaceutical research are expected to attend this year's AAPS Annual Meeting and Exposition November 8 - 12, 2009 at the Los Angeles Convention Center in California.

29 Sep 2009

The mysterious origin of Merkel cells

A new study resolves a 130-year-old mystery over the developmental origin of specialized skin cells involved in touch sensation. The findings will appear in the October 5, 2009 issue of the Journal of Cell Biology (online September 28).

29 Sep 2009

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Proton therapy center to treat pediatric and adult cancer patients

The development of a proton therapy center in the Pacific Northwest has taken a significant step forward with the signing of a letter of intent between the Seattle Cancer Care Alliance (SCCA) and ProCure Treatment Centers Inc. (ProCure). SCCA and ProCure announced the agreement today and are moving the project forward to bring this advanced form of radiation therapy to adult and pediatric cancer patients.

29 Sep 2009

The CDH Proton Therapy Center announces arrival of a 220-ton cyclotron for treating cancer

A 220-ton cyclotron, the core of what will soon be Illinois’ most advanced radiation treatment center, has ended a 5,000-mile journey that began in Belgium, arriving at the construction site of the CDH Proton Therapy Center, a ProCure Center, located in suburban Warrenville. Capable of accelerating protons, the cyclotron is the core piece of equipment used in proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

28 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Health inequalities linked to socioeconomic status

Prostate cancer patients of low socioeconomic status are more likely to die than patients with higher incomes. That is the finding of a new study from Swiss researchers to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

28 Sep 2009